Patritumab Deruxtecan Is Efficacious in EGFR-Mutant Non–Small Cell Lung Cancer

Article navigation

Research Watch| December 12 2023

Online ISSN: 2159-8290

Print ISSN: 2159-8274

2023

American Association for Cancer Research

Cancer Discov (2023) 13 (12): 2501.

Abstract

Patritumab deruxtecan has clinical efficacy in previously treated EGFR-mutant non–small cell lung cancer.

2023

American Association for Cancer Research

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.